open access

Vol 6, No 6 (2010)
Review paper
Published online: 2011-02-24
Get Citation

The treatment of patients with metastatic renal cell carcinoma — facts or logic based on facts?

Anna Drosik, Kazimierz Drosik
Onkol. Prak. Klin 2010;6(6):311-317.

open access

Vol 6, No 6 (2010)
REVIEW ARTICLES
Published online: 2011-02-24

Abstract

For many years cytokines were the only treatment for patients with metastatic renal cell cancer. However, this therapy was beneficial only for small group of patients with slow natural course of the disease. The situation has changed after introducing novel ,so called, targeted drugs, which inhibits intra- and extracellular signalling. Question that remains unanswered is the optimal use of these new therapeutic options. We present results of clinical trials evaluating these drugs and possible interpretation of their results, which constitute the basis of the european and american guidelines for systemic treatment of metastatic renal cell carcinoma.

Onkol. Prak. Klin. 2010; 6, 6: 311–317

Abstract

For many years cytokines were the only treatment for patients with metastatic renal cell cancer. However, this therapy was beneficial only for small group of patients with slow natural course of the disease. The situation has changed after introducing novel ,so called, targeted drugs, which inhibits intra- and extracellular signalling. Question that remains unanswered is the optimal use of these new therapeutic options. We present results of clinical trials evaluating these drugs and possible interpretation of their results, which constitute the basis of the european and american guidelines for systemic treatment of metastatic renal cell carcinoma.

Onkol. Prak. Klin. 2010; 6, 6: 311–317

Get Citation

Keywords

renal cell carcinoma; systemic therapy; guidelines

About this article
Title

The treatment of patients with metastatic renal cell carcinoma — facts or logic based on facts?

Journal

Oncology in Clinical Practice

Issue

Vol 6, No 6 (2010)

Article type

Review paper

Pages

311-317

Published online

2011-02-24

Bibliographic record

Onkol. Prak. Klin 2010;6(6):311-317.

Keywords

renal cell carcinoma
systemic therapy
guidelines

Authors

Anna Drosik
Kazimierz Drosik

References (21)
  1. Potemski P. Czy znajomość biologii molekularnej raka nerki ma już dla onkologa znaczenie praktyczne? Poszukiwanie czynników predykcyjnych dla nowych leków. Onkol Prak Klin. 2010; 6: 14–20.
  2. Żołnierek J. Leczenie sekwencyjne z zastosowaniem inhibitorów kinaz u chorych z rozsianym rakiem nerki. Onkol Prak Klin. 2010; 6: 21–28.
  3. Flanigan RC, Mickisch G, Sylvester R, et al. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol. 2004; 171(3): 1071–1076.
  4. Escudier B, Pluzanska A, Koralewski P, et al. AVOREN Trial investigators. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007; 370(9605): 2103–2111.
  5. Melichar B, Koralewski P, Ravaud A, et al. First-line bevacizumab combined with reduced dose interferon-alpha2a is active in patients with metastatic renal cell carcinoma. Ann Oncol. 2008; 19(8): 1470–1476.
  6. Rini BI, Halabi S, Rosenberg JE, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol. 2008; 26(33): 5422–5428.
  7. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res. 2003; 9(1): 327–337.
  8. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007; 356(2): 115–124.
  9. Hutson TE, Davis ID, Machiels JPH, et al. Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2010; 28(3): 475–480.
  10. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010; 28(6): 1061–1068.
  11. Schmelzle T, Hall MN. TOR, a central controller of cell growth. Cell. 2000; 103(2): 253–262.
  12. Fingar DC, Richardson CJ, Tee AR, et al. mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Mol Cell Biol. 2004; 24(1): 200–216.
  13. Atkins MB, Hidalgo M, Stadler WM, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol. 2004; 22(5): 909–918.
  14. Hudes GR, Carducci MA, Choueiri TK, et al. Global ARCC Trial. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007; 356(22): 2271–2281.
  15. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004; 64(19): 7099–7109.
  16. Escudier B, Eisen T, Stadler WM, et al. TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007; 356(2): 125–134.
  17. Escudier B, Eisen T, Stadler WM, et al. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol. 2009; 27(20): 3312–3318.
  18. Harris TE, Lawrence JC. TOR signaling. Sci STKE. 2003; 2003(212): re15.
  19. Motzer RJ, Escudier B, Oudard S, et al. RECORD-1 Study Group. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008; 372(9637): 449–456.
  20. Escudier B, Kataja V. and On behalf of the ESMO Guidelines Working Group Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2009; 20: 81–82.
  21. NCCN. Kidney Cancer. T.2. http://www.nccn.org/interactive/podcasts/mp3/annual_conference_2009/Kidney_GLs.asp..

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl